SEC Form S-3ASR filed by Regeneron Pharmaceuticals Inc.
SECURITIES AND EXCHANGE COMMISSION
UNDER
THE SECURITIES ACT OF 1933
|
New York
(State or Other Jurisdiction of
Incorporation or Organization) |
| |
13-3444607
(I.R.S. Employer
Identification No.) |
|
Tarrytown, New York 10591-6707
(914) 847-7000
Executive Vice President, General Counsel and Secretary
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
(914) 847-7000
Skadden, Arps, Slate, Meagher & Flom LLP
One Manhattan West
New York, New York 10001
Telephone: (212) 735-3000
|
Large accelerated filer
☒
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☐
|
| |
Smaller reporting company
☐
|
|
| | | |
Emerging growth company
☐
|
|
PREFERRED STOCK
DEBT SECURITIES
WARRANTS
| | |
Page
|
| |||
| | | | ii | | | |
| | | | iii | | | |
| | | | iv | | | |
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 8 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | |
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 847-7000
|
Securities and Exchange Commission Registration Fee
|
| | | $ | * | | |
|
Accounting Fees and Expenses
|
| | | $ | ** | | |
|
Legal Fees and Expenses
|
| | | $ | ** | | |
|
Printing Fees
|
| | | $ | ** | | |
|
Transfer Agent and Trustees’ Fees and Expenses
|
| | | $ | ** | | |
|
Rating Agency Fees
|
| | | $ | ** | | |
|
Stock Exchange Listing Fees
|
| | | $ | ** | | |
|
Miscellaneous
|
| | | $ | ** | | |
|
Total
|
| | | $ | ** | | |
| REGENERON PHARMACEUTICALS, INC. | | ||||||
| By: | | | /s/ CHRISTOPHER FENIMORE | | |||
| | | | Name: | | | Christopher Fenimore | |
| | | | Title: | | |
Senior Vice President, Finance and
Chief Financial Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ LEONARD S. SCHLEIFER
Leonard S. Schleifer, M.D., Ph.D.
|
| |
Board co-Chair, President and
Chief Executive Officer (Principal Executive Officer) |
| |
October 31, 2024
|
|
|
/s/ CHRISTOPHER FENIMORE
Christopher Fenimore
|
| |
Senior Vice President, Finance and Chief Financial Officer
(Principal Financial Officer) |
| |
October 31, 2024
|
|
|
/s/ JASON PITOFSKY
Jason Pitofsky
|
| |
Vice President, Controller
(Principal Accounting Officer) |
| |
October 31, 2024
|
|
|
/s/ GEORGE D. YANCOPOULOS
George D. Yancopoulos, M.D., Ph.D.
|
| |
Board co-Chair, President and
Chief Scientific Officer |
| |
October 31, 2024
|
|
|
/s/ BONNIE L. BASSLER
Bonnie L. Bassler, Ph.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ MICHAEL S. BROWN
Michael S. Brown, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ N. ANTHONY COLES
N. Anthony Coles, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ JOSEPH L. GOLDSTEIN
Joseph L. Goldstein, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ KATHRYN GUARINI
Kathryn Guarini, Ph.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ CHRISTINE A. POON
Christine A. Poon
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ ARTHUR F. RYAN
Arthur F. Ryan
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ DAVID P. SCHENKEIN
David P. Schenkein, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ GEORGE L. SING
George L. Sing
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ CRAIG B. THOMPSON
Craig B. Thompson, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|
|
/s/ HUDA Y. ZOGHBI
Huda Y. Zoghbi, M.D.
|
| |
Director
|
| |
October 31, 2024
|
|